Creating #preciselytargetedtherapies for patients with cancer, designed to overcome limitations of existing therapies for clinically proven kinase targets

Cambridge, MA
Joined January 2021
Today, Nuvalent officially becomes part of GSK. Building on our legacy of strong science and commitment to patients, we look forward to continuing to advance innovative, precisely targeted medicines for people living with cancer, together. Learn more: gsk.to/3T1uzts
4
1
7
963
Oncology care is a coordinated effort built on expertise, communication, and trust, with patients and clinicians partnering in informed decision-making. Gail’s advice reminds us of the importance of leaning on your care team for support as you navigate your treatment journey.
2
211
Knowledge is power when facing a #LungCancer diagnosis. Did you know that broader awareness of NSCLC subtypes and #EarlyDetection through biomarker testing are critical to more informed care? Find FAQs on ROS1+ or ALK+ NSCLC here on: elevatelungcancercare.com.
3
7
322
Last week, some of our #NuCrew colleagues laced up their running shoes and took on the Boston @jpmorgan Corporate Challenge! Teamwork, fresh air, and skyline views made for a great evening celebrating connection beyond our desks. Proud of all who ran and cheered!
5
228
This year’s 20th Annual Bio-Ball tournament was a SLAM DUNK! 🏀🔥 Unforgettable moments with the @SpOlympicsMA athletes and the #NuCrew. We are proud to support an organization that promotes inclusion, empowerment, and the power of sport!
1
5
197
Advocacy can help drive meaningful change for patients with ALK+ #LungCancer. Empower yourself and ensure your voice is heard with a tailored care plan. Explore our doctor discussion guide and other patient resources at elevatelungcancercare.com/AL…
5
8
417
Nuvalent retweeted
#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy
4
4
11
2,304
That’s a wrap on the 2026 @ASCO Annual Meeting. The #NuCrew had a great time connecting with the #oncology community and presenting clinical updates from our #ALK+ #NSCLC and #ROS1+ programs. Thanks to all who joined for our oral presentation and stopped by our poster. #ASCO26
1
6
304
Today on #NationalCancerSurvivorsDay, we recognize the strength and resilience of all #CancerSurvivors, including those facing the unique challenges of ALK+ and ROS1+ #LungCancer. To patients, caregivers, and loved ones: we stand with you.💪 #ALKPositive #ROS1Positive
1
2
8
291
Proud to stand with @ALKPositiveinc & the ALK #LungCancer community for #ALKAwarenessMonth!🎗️#FuelTheCure honors the patients, researchers & advocates driving progress. Together, we fuel hope, research & innovation. #APAM26
1
10
239
We are excited to share that the FDA has accepted for filing with Priority Review our NDA for neladalkib, our investigational ALK-selective inhibitor in TKI pre-treated advanced ALK-positive #NSCLC with a PDUFA date of November 27, 2026.
2
7
1
25
2,361
Join us at the 2026 @ASCO Annual Meeting, where we’ll present clinical updates from our #ALK+ #NSCLC and ROS1+ programs. Learn more here. investors.nuvalent.com/2026-… #ASCO26
3
10
687
We recognize the emotional weight of a #LungCancer journey. This #MentalHealthAwareness month, find strength through support. Connect with patient advocacy groups like @ALKPositiveinc and @ros1cancer, where patients & caregivers come together to share and uplift one another.
2
1
11
240
This morning, we reported our Q1 2026 financial results, along with recent pipeline and business progress and anticipated milestones. Learn more here. investors.nuvalent.com/2026-…
1
1
4
332
The #NuCrew had a great time @AACR 2026 engaging with the #oncology community and presenting new data for our #ROS1+ #NSCLC program. Thanks to all who stopped by our posters! #AACR26
1
7
184
Join us in welcoming Riley, Ashley, Kyle, and Tiffany to the #NuCrew! 🎉 We’re excited to have them on board!
2
252
Join us at the 2026 @ASCO Annual Meeting in Chicago where we'll present clinical updates from our #ALK+ #NSCLC and #ROS1+ programs. Learn more: investors.nuvalent.com/2026-… #ASCO26
5
9
1,096
This week at @AACR 2026, we're pleased to share new clinical and preclinical data for our #ROS1 + #NSCLC program. Learn more here. investors.nuvalent.com/2026-…
2
8
867
During #CancerPrevention and #EarlyDetection Month, we’re honoring the stories of patients like Luna and Brandi. Through biomarker testing, they discovered important answers that helped guide their treatment journeys. Learn about ROS1 & ALK+ NSCLC & more→elevatelungcancercare.com.
1
3
307